Caas Capital Management LP Acquires Shares of 144,308 Cencora, Inc. (NYSE:COR)
Caas Capital Management LP acquired a new stake in shares of Cencora, Inc. (NYSE:COR – Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 144,308 shares of the company’s stock, valued at approximately $27,769,000. Cencora makes up 1.9% of Caas Capital Management LP’s investment portfolio, making the stock its largest position. Caas Capital Management LP owned approximately 0.07% of Cencora at the end of the most recent reporting period.
Several other institutional investors have also added to or reduced their stakes in COR. Tilia Fiduciary Partners Inc. increased its holdings in shares of Cencora by 321.2% during the second quarter. Tilia Fiduciary Partners Inc. now owns 139 shares of the company’s stock worth $27,000 after buying an additional 106 shares in the last quarter. Harbour Investments Inc. increased its holdings in shares of Cencora by 61.8% during the first quarter. Harbour Investments Inc. now owns 165 shares of the company’s stock worth $26,000 after buying an additional 63 shares in the last quarter. Creative Financial Designs Inc. ADV increased its holdings in shares of Cencora by 50.9% during the second quarter. Creative Financial Designs Inc. ADV now owns 175 shares of the company’s stock worth $34,000 after buying an additional 59 shares in the last quarter. Cascade Investment Advisors Inc. acquired a new position in shares of Cencora during the first quarter worth $32,000. Finally, Altshuler Shaham Ltd acquired a new position in shares of Cencora during the second quarter worth $40,000. 93.12% of the stock is currently owned by institutional investors and hedge funds.
Cencora Trading Up 0.8 %
COR traded up $1.54 during trading on Friday, reaching $201.75. 1,441,832 shares of the stock traded hands, compared to its average volume of 1,702,714. The company has a quick ratio of 0.52, a current ratio of 0.88 and a debt-to-equity ratio of 6.22. The stock has a market capitalization of $40.49 billion, a PE ratio of 23.65, a P/E/G ratio of 1.74 and a beta of 0.55. The stock’s 50-day moving average is $193.02 and its 200 day moving average is $185.09. Cencora, Inc. has a 12 month low of $147.48 and a 12 month high of $205.83.
Cencora (NYSE:COR – Get Free Report) last issued its quarterly earnings results on Thursday, November 2nd. The company reported $2.86 EPS for the quarter, beating analysts’ consensus estimates of $2.79 by $0.07. The business had revenue of $68.92 billion for the quarter, compared to analysts’ expectations of $66.57 billion. Cencora had a net margin of 0.67% and a return on equity of 451.42%. Equities analysts anticipate that Cencora, Inc. will post 12.88 earnings per share for the current year.
Cencora Increases Dividend
The company also recently declared a quarterly dividend, which was paid on Monday, November 27th. Shareholders of record on Monday, November 13th were given a dividend of $0.51 per share. The ex-dividend date was Friday, November 10th. This represents a $2.04 dividend on an annualized basis and a yield of 1.01%. This is a boost from Cencora’s previous quarterly dividend of $0.49. Cencora’s dividend payout ratio is 23.92%.
Insider Buying and Selling at Cencora
In other news, EVP Gina Clark sold 10,695 shares of the stock in a transaction dated Tuesday, October 10th. The shares were sold at an average price of $187.00, for a total transaction of $1,999,965.00. Following the transaction, the executive vice president now owns 16,038 shares of the company’s stock, valued at approximately $2,999,106. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, EVP Gina Clark sold 10,695 shares of the stock in a transaction dated Tuesday, October 10th. The shares were sold at an average price of $187.00, for a total transaction of $1,999,965.00. Following the transaction, the executive vice president now owns 16,038 shares of the company’s stock, valued at approximately $2,999,106. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Lazarus Krikorian sold 2,000 shares of the stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $203.60, for a total transaction of $407,200.00. Following the transaction, the chief accounting officer now directly owns 19,876 shares in the company, valued at approximately $4,046,753.60. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 1,345,672 shares of company stock valued at $262,650,480. 1.40% of the stock is currently owned by insiders.
Wall Street Analysts Forecast Growth
Several brokerages have recently issued reports on COR. StockNews.com downgraded shares of Cencora from a “strong-buy” rating to a “buy” rating in a report on Friday. TheStreet upgraded shares of Cencora from a “c” rating to a “b” rating in a report on Monday, October 9th. Finally, Evercore ISI boosted their price objective on shares of Cencora from $210.00 to $225.00 in a research note on Wednesday, October 11th. Two investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat.com, Cencora presently has an average rating of “Moderate Buy” and an average price target of $197.36.
Read Our Latest Stock Report on Cencora
Cencora Company Profile (Free Report)
Cencora, Inc sources and distributes pharmaceutical products. The company’s U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.
See Also
Want to see what other hedge funds are holding COR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cencora, Inc. (NYSE:COR – Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Cencora, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Cencora wasn’t on the list.
While Cencora currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Original: MarketBeat News Feed: Caas Capital Management LP Acquires Shares of 144,308 Cencora, Inc. (NYSE:COR)